TORRENT-PIOGLITAZONE TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)

Commercializzato da:

TORRENT PHARMACEUTICALS LIMITED

Codice ATC:

A10BG03

INN (Nome Internazionale):

PIOGLITAZONE

Dosaggio:

30MG

Forma farmaceutica:

TABLET

Composizione:

PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

Prescription

Area terapeutica:

THIAZOLIDINEDIONES

Dettagli prodotto:

Active ingredient group (AIG) number: 0141541002; AHFS:

Stato dell'autorizzazione:

CANCELLED (UNRETURNED ANNUAL)

Data dell'autorizzazione:

2021-12-20

Scheda tecnica

_ _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
TORRENT-PIOGLITAZONE
Pioglitazone Tablets USP
15 mg, 30 mg and 45 mg
(pioglitazone as pioglitazone hydrochloride)
Anti-Diabetic Agent
Manufacturer:
Torrent Pharmaceuticals Ltd.
Indrad – 382 721
Dist. Mehsana
India
Distributor:
Torrent Pharma Canada Inc.
Woodbridge, ON L4H 2K4
Submission Control: 163888
Date of Revision:
December 04, 2013
_ _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
CLINICAL TRIALS
..............................................................................